Some Ebola guidelines questioned

Experts questions questioning calls for suspending certain routine lab tests


Experts are questioning aspects of some of the Ebola guidelines that go beyond current Centers for Disease Control and Prevention (CDC) recommendations, especially those that call for suspending certain routine lab tests, according to an article on Infection Control Today.

A commentary in the journal Transfusion suggests that most individuals with suspected Ebola will have a fever due to another cause, and forgoing such testing may compromise patients' health more than any reduction in the risks to laboratory personnel.

The article says that all laboratory directors must work with infection control and safety experts to evaluate their hospital policies on potentially infectious patients to provide a safe environment.

Read the article.

 

 



December 12, 2014


Topic Area: Safety


Recent Posts

Why Identity Governance Is Becoming a Facilities Management Issue

As healthcare buildings grow more connected, weak identity controls can expose HVAC, security and other critical systems to serious risk.


Habitat Health Opens South Los Angeles PACE Center

The new center strengthens the local care infrastructure, delivering integrated medical, social and in-home care.


Denton County MHMR Center Suffers a Data Breach

The incident occurred on or around December 24, 2024.


What Every EVS Leader Needs To Know

Managers must demonstrate mastery of infection prevention standards, accountability through measurable outcomes and visible collaboration with clinical teams.


Blackbird Health Opens New Clinic in New Jersey

The new clinic is located in Mount Laurel.


 
 


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!

 
 
 


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 
 
 
 

Healthcare Facilities Today membership includes free email newsletters from our facility-industry brands.

Facebook   Twitter   LinkedIn   Posts

Copyright © 2023 TradePress. All rights reserved.